{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:28:34Z","timestamp":1789072114408,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-023-02044-3","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T07:19:03Z","timestamp":1683789543000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Cancer-biomarkers associated with sex hormone receptors and recent therapeutic advancements: a comprehensive review"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5204-6121","authenticated-orcid":false,"given":"Suvitha","family":"Anbarasu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2216-7488","authenticated-orcid":false,"given":"Anand","family":"Anbarasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,10]]},"reference":[{"key":"2044_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-022-03554-y","author":"M Ahmed","year":"2022","unstructured":"Ahmed M, M\u00e4kinen V-P, Mulugeta A, Shin J, Boyle T, Hypp\u00f6nen E, Lee SH. Considering hormone-sensitive cancers as a single disease in the UK biobank reveals shared aetiology. Commun Biol. 2022. https:\/\/doi.org\/10.1038\/s42003-022-03554-y.","journal-title":"Commun Biol"},{"key":"2044_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2019.04.016","author":"K Gonthier","year":"2019","unstructured":"Gonthier K, Poluri RTK, Audet-Walsh \u00c9. Functional genomic studies reveal the androgen receptor as a master regulator of cellular energy metabolism in prostate cancer. J Steroid Biochem Mol Biol. 2019. https:\/\/doi.org\/10.1016\/j.jsbmb.2019.04.016.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2044_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.612396","author":"C \u015eoica","year":"2021","unstructured":"\u015eoica C, Voicu M, Ghiulai R, Dehelean C, Racoviceanu R, Trandafirescu C, Ro\u0219ca OJ, Nistor G, Mioc M, Mioc A. Natural compounds in sex hormone-dependent cancers: the role of triterpenes as therapeutic agents. Front Endocrinol. 2021. https:\/\/doi.org\/10.3389\/fendo.2020.612396.","journal-title":"Front Endocrinol"},{"key":"2044_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.genrep.2021.101101","author":"G Ashok","year":"2021","unstructured":"Ashok G, Miryala SK, Anbarasu A, Ramaiah S. Integrated systems biology approach using gene network analysis to identify the important pathways and new potential drug targets for Neuroblastoma. Gene Rep. 2021. https:\/\/doi.org\/10.1016\/j.genrep.2021.101101.","journal-title":"Gene Rep"},{"key":"2044_CR5","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ejphar.2018.07.034","volume":"834","author":"YT Lee","year":"2018","unstructured":"Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: treating cancer with specificity. Eur J Pharmacol. 2018;834:188\u201396. https:\/\/doi.org\/10.1016\/j.ejphar.2018.07.034.","journal-title":"Eur J Pharmacol"},{"key":"2044_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/medicina55090573","author":"M D\u2019Alonzo","year":"2019","unstructured":"D\u2019Alonzo M, Bounous VE, Villa M, Biglia N. Current evidence of the oncological benefit-risk profile of hormone replacement therapy. Medicina (Lithuania). 2019. https:\/\/doi.org\/10.3390\/medicina55090573.","journal-title":"Medicina (Lithuania)"},{"issue":"6","key":"2044_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12061647","volume":"12","author":"SP Langdon","year":"2020","unstructured":"Langdon SP, Herrington CS, Hollis RL, Gourley C. Estrogen signaling and its potential as a target for therapy in ovarian cancer. Cancers. 2020;12(6):1\u201317. https:\/\/doi.org\/10.3390\/cancers12061647.","journal-title":"Cancers"},{"issue":"1","key":"2044_CR8","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1210\/er.2012-1043","volume":"34","author":"JJ Kim","year":"2013","unstructured":"Kim JJ, Kurita T, Bulun SE. Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. Endocr Rev. 2013;34(1):130\u201362. https:\/\/doi.org\/10.1210\/er.2012-1043.","journal-title":"Endocr Rev"},{"key":"2044_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13235953","author":"JJ Peluso","year":"2021","unstructured":"Peluso JJ, Pru JK. Progesterone receptor membrane component (Pgrmc)1 and pgrmc2 and their roles in ovarian and endometrial cancer. Cancers. 2021. https:\/\/doi.org\/10.3390\/cancers13235953.","journal-title":"Cancers"},{"key":"2044_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/cells8020176","author":"T Mizushima","year":"2019","unstructured":"Mizushima T, Miyamoto H. The role of androgen receptor signaling in ovarian cancer. Cells. 2019. https:\/\/doi.org\/10.3390\/cells8020176.","journal-title":"Cells"},{"key":"2044_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23147556","author":"S Wu","year":"2022","unstructured":"Wu S, Yu K, Lian Z, Deng S. Molecular regulation of androgen receptors in major female reproductive system cancers. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23147556.","journal-title":"Int J Mol Sci"},{"key":"2044_CR12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s004419900159","volume":"301","author":"R Medh","year":"2000","unstructured":"Medh R, Thompson E. Hormonal regulation of physiological cell turnover and apoptosis. Cell Tissue Res 2000;301:101\u201324. https:\/\/doi.org\/10.1007\/s004419900159","journal-title":"Cell Tissue Res"},{"key":"2044_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.673180","author":"A Losada-Garc\u00eda","year":"2022","unstructured":"Losada-Garc\u00eda A, Cort\u00e9s-Ram\u00edrez SA, Cruz-Burgos M, Morales-Pacheco M, Cruz-Hern\u00e1ndez CD, Gonzalez-Covarrubias V, Perez-Plascencia C, Cerb\u00f3n MA, Rodr\u00edguez-Dorantes M. Hormone-related cancer and autoimmune diseases: a complex interplay to be discovered. Front Genet. 2022. https:\/\/doi.org\/10.3389\/fgene.2021.673180.","journal-title":"Front Genet"},{"key":"2044_CR14","unstructured":"Ferlay J, (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer."},{"issue":"3","key":"2044_CR15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.5144\/1658-3876.2012.127","volume":"5","author":"G Orphanos","year":"2012","unstructured":"Orphanos G, Kountourakis P. Targeting the HER2 receptor in metastatic breast cancer. Hematol Oncol Stem Cell Ther. 2012;5(3):127\u201337. https:\/\/doi.org\/10.5144\/1658-3876.2012.127.","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"2044_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2019.00730","author":"EA Pudova","year":"2019","unstructured":"Pudova EA, Lukyanova EN, Nyushko KM, Mikhaylenko DS, Zaretsky AR, Snezhkina AV, Savvateeva MV, Kobelyatskaya AA, Melnikova NV, Volchenko NN, Efremov GD, Klimina KM, Belova AA, Kiseleva MV, Kaprin AD, Alekseev BY, Krasnov GS, Kudryavtseva AV. Differentially expressed genes associated with prognosis in locally advanced lymph node-negative prostate cancer. Front Genet. 2019. https:\/\/doi.org\/10.3389\/fgene.2019.00730.","journal-title":"Front Genet"},{"key":"2044_CR17","doi-asserted-by":"publisher","unstructured":"Qi L, Sun B, Yang B, Lu S. Detection of biomarkers related to the diagnosis and prognosis of breast cancer through the combination of gene expression profiling and DNA methylation. 2022. https:\/\/doi.org\/10.21203\/rs.3.rs-1516257\/v1","DOI":"10.21203\/rs.3.rs-1516257\/v1"},{"key":"2044_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cells8020089","author":"N Gandhi","year":"2019","unstructured":"Gandhi N, Das GM. Metabolic reprogramming in breast cancer and its therapeutic implications. Cells. 2019. https:\/\/doi.org\/10.3390\/cells8020089.","journal-title":"Cells"},{"issue":"1\u20132","key":"2044_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s10911-015-9340-5","volume":"20","author":"J Finlay-Schultz","year":"2015","unstructured":"Finlay-Schultz J, Sartorius CA. Steroid hormones, steroid receptors, and breast cancer stem cells. J Mammary Gland Biol Neoplasia. 2015;20(1\u20132):39\u201350. https:\/\/doi.org\/10.1007\/s10911-015-9340-5.","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"2044_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/284036","volume":"2013","author":"GM Higa","year":"2013","unstructured":"Higa GM, Fell RG. Sex hormone receptor repertoire in breast cancer. Int J Breast Cancer. 2013;2013:1\u201314. https:\/\/doi.org\/10.1155\/2013\/284036.","journal-title":"Int J Breast Cancer"},{"issue":"17\u201318","key":"2044_CR21","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1101\/gad.316646.118","volume":"32","author":"R Siersb\u00e6k","year":"2018","unstructured":"Siersb\u00e6k R, Kumar S, Carroll JS. Signaling pathways and steroid receptors modulating estrogen receptor \u03b1 function in breast cancer. Genes Dev. 2018;32(17\u201318):1141\u201354. https:\/\/doi.org\/10.1101\/gad.316646.118.","journal-title":"Genes Dev"},{"issue":"1","key":"2044_CR22","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10549-015-3594-x","volume":"154","author":"SA Haddad","year":"2015","unstructured":"Haddad SA, Lunetta KL, Ruiz-Narv\u00e1ez EA, Bensen JT, Hong CC, Sucheston-Campbell LE, Yao S, Bandera E, v., Rosenberg, L., Haiman, C. A., Troester, M. A., Ambrosone, C. B., & Palmer, J. R. Hormone-related pathways and risk of breast cancer subtypes in African American women. Breast Cancer Res Treat. 2015;154(1):145\u201354. https:\/\/doi.org\/10.1007\/s10549-015-3594-x.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"2044_CR23","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/carcin\/21.3.427","volume":"21","author":"BE Henderson","year":"2000","unstructured":"Henderson BE, Feigelson HS. Hormonal carcinogenesis the key distinction between this \u201ccell proliferation\u201d model. Carcinogenesis. 2000;21(3):427\u201333.","journal-title":"Carcinogenesis"},{"issue":"4","key":"2044_CR24","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.eururo.2017.10.036","volume":"73","author":"V Cucchiara","year":"2018","unstructured":"Cucchiara V, Cooperberg MR, Dall\u2019Era M, Lin DW, Montorsi F, Schalken JA, Evans CP. Genomic markers in prostate cancer decision making. Eur Urol. 2018;73(4):572\u201382. https:\/\/doi.org\/10.1016\/j.eururo.2017.10.036.","journal-title":"Eur Urol"},{"key":"2044_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-019-0367-x","author":"Y Shen","year":"2019","unstructured":"Shen Y, Cao J, Liang Z, Lin Q, Wang J, Yang X, Zhang R, Zong J, Du X, Peng Y, Zhang J, Shi J. Estrogen receptor \u03b1-NOTCH1 axis enhances basal stem-like cells and epithelial-mesenchymal transition phenotypes in prostate cancer. Cell Commun Signal. 2019. https:\/\/doi.org\/10.1186\/s12964-019-0367-x.","journal-title":"Cell Commun Signal"},{"issue":"6","key":"2044_CR26","doi-asserted-by":"publisher","first-page":"R339","DOI":"10.1530\/ERC-14-0550","volume":"22","author":"H Gharwan","year":"2015","unstructured":"Gharwan H, Bunch KP, Annunziata CM. The role of reproductive hormones in epithelial ovarian carcinogenesis. Endocr Relat Cancer. 2015;22(6):R339\u201393. https:\/\/doi.org\/10.1530\/ERC-14-0550.","journal-title":"Endocr Relat Cancer"},{"key":"2044_CR27","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/475983","author":"A Agarwal","year":"2011","unstructured":"Agarwal A, Rein BJD, Gupta S, Dada R, Safi J, Michener C. Potential markers for detection and monitoring of ovarian cancer. J Oncol. 2011. https:\/\/doi.org\/10.1155\/2011\/475983.","journal-title":"J Oncol"},{"key":"2044_CR28","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jsbmb.2018.01.011","volume":"178","author":"M Sinreih","year":"2018","unstructured":"Sinreih M, Knific T, Thomas P, Frkovi\u0107 Grazio S, Ri\u017ener TL. Membrane progesterone receptors \u03b2 and \u03b3 have potential as prognostic biomarkers of endometrial cancer. J Steroid Biochem Mol Biol. 2018;178:303\u201311. https:\/\/doi.org\/10.1016\/j.jsbmb.2018.01.011.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"2\u20133","key":"2044_CR29","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s12672-019-0358-9","volume":"10","author":"AC Rodriguez","year":"2019","unstructured":"Rodriguez AC, Blanchard Z, Maurer KA, Gertz J. Estrogen signaling in endometrial cancer: a key oncogenic pathway with several open questions. Hormon Cancer. 2019;10(2\u20133):51\u201363. https:\/\/doi.org\/10.1007\/s12672-019-0358-9.","journal-title":"Hormon Cancer"},{"key":"2044_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-020-00563-4","author":"Z Chen","year":"2020","unstructured":"Chen Z, Yang HJ, Lin Q, Zhu MJ, Yu YY, He XY, Wan XP. Estrogen-ER\u03b1 signaling and DNA hypomethylation co-regulate expression of stem cell protein PIWIL1 in ER\u03b1-positive endometrial cancer cells. Cell Communication and Signaling. 2020. https:\/\/doi.org\/10.1186\/s12964-020-00563-4.","journal-title":"Cell Communication and Signaling"},{"issue":"2","key":"2044_CR31","doi-asserted-by":"publisher","first-page":"R10","DOI":"10.1530\/EC-18-0425","volume":"8","author":"M Ulm","year":"2019","unstructured":"Ulm M, Ramesh AV, McNamara KM, Ponnusamy S, Sasano H, Narayanan R. Therapeutic advances in hormone-dependent cancers: focus on prostate, breast, and ovarian cancers. Endocr Conn. 2019;8(2):R10\u201326. https:\/\/doi.org\/10.1530\/EC-18-0425.","journal-title":"Endocr Conn"},{"issue":"3","key":"2044_CR32","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.cpet.2018.02.006","volume":"13","author":"TA Moo","year":"2018","unstructured":"Moo TA, Sanford R, Dang C, Morrow M. Overview of breast cancer therapy. PET Clinics. 2018;13(3):339\u201354. https:\/\/doi.org\/10.1016\/j.cpet.2018.02.006.","journal-title":"PET Clinics"},{"issue":"3","key":"2044_CR33","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/j.1939-4640.2004.tb02791.x","volume":"25","author":"F Labrie","year":"2004","unstructured":"Labrie F. Medical castration with LHRH agonists: 25 years later with major benefits achieved on survival in prostate cancer. J Androl. 2004;25(3):305\u201313. https:\/\/doi.org\/10.1002\/j.1939-4640.2004.tb02791.x.","journal-title":"J Androl"},{"key":"2044_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19051359","author":"E Nevedomskaya","year":"2018","unstructured":"Nevedomskaya E, Baumgart SJ, Haendler B. Recent advances in prostate cancer treatment and drug discovery. Int J Mol Sci. 2018. https:\/\/doi.org\/10.3390\/ijms19051359.","journal-title":"Int J Mol Sci"},{"key":"2044_CR35","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.\u010335","author":"S Sumanasuriya","year":"2018","unstructured":"Sumanasuriya S, de Bono J. Treatment of advanced prostate cancer\u2014a review of current therapies and future promise. Cold Spring Harbor Perspect Med. 2018. https:\/\/doi.org\/10.1101\/cshperspect.\u010335.","journal-title":"Cold Spring Harbor Perspect Med"},{"issue":"12","key":"2044_CR36","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/nejmoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, Kopyltsov E, Park CH, Alekseev B, Montesa-Pino \u00c1, Ye D, Parnis F, Cruz F, Tammela TLJ, Suzuki H, Utriainen T, Fu C, Uemura M, M\u00e9ndez-Vidal MJ, Maughan Benjamin L, Joensuu Heikki, Thiele Silke, Li Rui, Kuss Iris, Tombal B. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. New Engl J Med. 2022;386(12):1132\u201342. https:\/\/doi.org\/10.1056\/nejmoa2119115.","journal-title":"New Engl J Med"},{"key":"2044_CR37","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jconrel.2016.10.014","volume":"243","author":"J Sapiezynski","year":"2016","unstructured":"Sapiezynski J, Taratula O, Rodriguez-Rodriguez L, Minko T. Precision targeted therapy of ovarian cancer. J Controlled Release. 2016;243:250\u201368. https:\/\/doi.org\/10.1016\/j.jconrel.2016.10.014.","journal-title":"J Controlled Release"},{"issue":"6","key":"2044_CR38","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3747\/co.v17i6.676","volume":"17","author":"Y Pan","year":"2010","unstructured":"Pan Y, Kao MS. Endometrioid ovarian carcinoma benefits from aromatase inhibitors: case report and literature review. Curr Oncol. 2010;17(6):82\u20135.","journal-title":"Curr Oncol"},{"key":"2044_CR39","doi-asserted-by":"publisher","DOI":"10.3892\/or.2021.8174","author":"H Li","year":"2021","unstructured":"Li H, Liu Y, Wang Y, Zhao X, Qi X. Hormone therapy for ovarian cancer: emphasis on mechanisms and applications (Review). Oncol Rep. 2021. https:\/\/doi.org\/10.3892\/or.2021.8174.","journal-title":"Oncol Rep"},{"issue":"9","key":"2044_CR40","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1080\/14728222.2016.1180368","volume":"20","author":"A Wagenfeld","year":"2016","unstructured":"Wagenfeld A, Saunders PTK, Whitaker L, Critchley HOD. Selective progesterone receptor modulators (SPRMs): progesterone receptor action, mode of action on the endometrium, and treatment options in gynecological therapies. Expert Opin Ther Targets. 2016;20(9):1045\u201354. https:\/\/doi.org\/10.1080\/14728222.2016.1180368.","journal-title":"Expert Opin Ther Targets"},{"key":"2044_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18071381","author":"S Lecomte","year":"2017","unstructured":"Lecomte S, Demay F, Ferri\u00e8re F, Pakdel F. Phytochemicals targeting estrogen receptors: beneficial rather than adverse effects? Int J Mol Sci. 2017. https:\/\/doi.org\/10.3390\/ijms18071381.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2044_CR42","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/jcp.24456","volume":"229","author":"A Ahmed","year":"2014","unstructured":"Ahmed A, Ali S, Sarkar FH. Advances in androgen receptor targeted therapy for prostate cancer. J Cell Physiol. 2014;229(3):271\u20136. https:\/\/doi.org\/10.1002\/jcp.24456.","journal-title":"J Cell Physiol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-02044-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-023-02044-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-02044-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T02:24:37Z","timestamp":1685067877000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-023-02044-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,10]]},"references-count":42,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["2044"],"URL":"https:\/\/doi.org\/10.1007\/s12032-023-02044-3","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,10]]},"assertion":[{"value":"15 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"171"}}